ReviewF1000Research2017
Challenges in microbiological diagnosis of invasive
Review in F1000Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Article
- A fully integrated sample-to-answer molecular diagnostic platform for rapid identification of four majorFrontiers in microbiology · 2026Article
- A silent invader: Invasive pulmonary aspergillosis in an immunocompetent host.Respiratory medicine case reports · 2026Article
- Article
- Mechanism-Based Pharmacokinetic/Pharmacodynamic Model of Voriconazole for Predicting the Clinical Outcomes of Adult Patients With Invasive Aspergillosis.Therapeutic drug monitoring · 2025Article
- Non-invasive monitoring ofFrontiers in cellular and infection microbiology · 2025Observational
- Reverse-transcriptase real-time PCR in the diagnostic strategy for invasive infections caused byJournal of clinical microbiology · 2024Article
- Invasive Mediastinal Aspergillosis in an 18-Year-Old Immunocompetent Female Leading to Stroke.Cureus · 2024Article
- Cross-sectional investigation of mycological diagnosis challenges in Saudi Arabia.Frontiers in cellular and infection microbiology · 2023Article
- Potential Antifungal Targets forInternational journal of molecular sciences · 2022Review
- Advantages and challenges of metagenomic sequencing for the diagnosis of pulmonary infectious diseases.The clinical respiratory journal · 2022Review
- A Complex Case of Aspergillus Infection of the Brain and Its Future Medical Implications.Cureus · 2022Article
- COVID-19-Associated Pulmonary Aspergillosis, Fungemia, and Pneumocystosis in the Intensive Care Unit: a Retrospective Multicenter Observational Cohort during the First French Pandemic Wave.Microbiology spectrum · 2021Observational
- Outbreak-Causing Fungi: Pneumocystis jirovecii.Mycopathologia · 2020Review
- Atti Le giornate della ricerca scientificae delle esperienze professionali dei giovani: Società Italiana di Igiene, Medicina Preventiva e Sanità Pubblica (SItI) Roma 20-21 dicembre 2019.Journal of preventive medicine and hygiene · 2020Article
- Treatment with etanercept and low monocyte concentration contribute to the risk of invasive aspergillosis in patients post allogeneic stem cell transplantation.Scientific reports · 2019Article
- The application of next-generation sequencing in diagnosing invasive pulmonary aspergillosis: three case reports.American journal of translational research · 2019Article
- Monitoring of Particle Environmental Pollution and Fungal Isolations During Hospital Building-Work Activities in a Hematology Ward.Mediterranean journal of hematology and infectious diseases · 2019Article
- Local retrospective analysis of galactomannan cut-off values in bronchoalveolar lavage fluids for diagnosis of invasive aspergillosis.Folia microbiologica · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Invasive aspergillosis (IA) has been increasingly reported in populations other than the historical hematology patients and there are new questions about the performance of microbiological tools. Microscopy and culture have been completed by biomarkers, either antigens or DNA, and in blood or respiratory specimens or both. First studied in hematology, the antigen galactomannan performance in serum is low in other patient populations where the pathophysiology of the infection can be different and the prevalence of IA is much lower. DNA detection with polymerase chain reaction (PCR) in blood or serum (or both) has reached a certain level of acceptance thanks to consensus methods based on real-time quantitative PCR (qPCR). When used on respiratory specimens, galactomannan and qPCR depend on standardization of the sampling and the diverse mycological procedures. Thus, culture remains the main diagnostic criterion in critically ill patients. The current trend toward more effective anti-mold prophylaxis in hematology hampers the yield of a screening strategy, as is usually performed in hematology. Therefore, circulating biomarkers as confirmatory tests should be considered and their performance should be reappraised in each new setting. The use of azole prophylaxis also raises the issue of selecting azole-resistance
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.